European Commission approves Roche's Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation
Up to 40% of ER-positive breast cancers have a PIK3CA mutation and are associated with poor prognosis; this approval helps address an urgent unmet need2-4
Itovebi is the first PI3K-targeted therapy to significantly extend survival, reinforcing the need for biomarker testing at diagnosis5
Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Itovebi™ (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment.
'Itovebi is the first treatment of its kind to improve survival outcomes for those living with PIK3CA-mutated, ER-positive advanced breast cancer,' said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. 'Therefore, the Itovebi-based regimen may help address an important unmet need for people with this subtype of breast cancer.'
The approval is based on results from the phase III INAVO120 trial, published in the New England Journal of Medicine in October 2024, which showed a 57% reduction in the risk of disease worsening or death (progression-free survival [PFS]) with the Itovebi-based regimen compared with palbociclib and fulvestrant alone (15.0 months vs. 7.3 months; hazard ratio [HR]=0.43; 95% CI: 0.32-0.59, p<0.001) in the first-line setting.1 The PFS benefit was consistent across all pre-specified subgroups and the Itovebi-based regimen was well tolerated, with no new safety signals observed.1
These results were reinforced by the INAVO120 final overall survival analysis that showed the Itovebi-based regimen reduced the risk of death by 33% (stratified HR=0.67; 95% CI: 0.48–0.94, p-value=0.0190 [boundary=0.0469]).5 Additionally, the treatment regimen substantially delayed the time to chemotherapy by approximately two years compared with palbociclib and fulvestrant alone (stratified HR=0.43; 95% CI: 0.30-0.60).5 These data were presented at the 2025 American Society of Clinical Oncology Annual Meeting and published in the New England Journal of Medicine in May 2025.
Beyond INAVO120, Itovebi is currently being investigated in three company-sponsored phase III studies (INAVO121, INAVO122, INAVO123), all in PIK3CA-mutated, locally advanced or metastatic breast cancer in various combinations.6-8 We are exploring additional studies in breast cancer and other tumour types with the hope of providing the benefit of this targeted therapy to more people with PIK3CA mutations.
About Itovebi TM (inavolisib)Itovebi is an oral, targeted treatment that has been shown to provide well-tolerated and durable disease control in people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced breast cancer, who often have a poor prognosis and are in urgent need of new treatment options.1,4,9 Itovebi has been designed to help minimise the overall burden and toxicity of treatment and is differentiated from other PI3K inhibitors due to its high potency and specificity for the PI3K alpha isoform versus other isoforms, and unique mechanism of action that facilitates the degradation of mutated PI3K alpha.10,11
In addition to the European Commission's approval, the Itovebi-based regimen is also approved for the treatment of adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer in the United States, Switzerland, Canada, Australia, United Arab Emirates, China and Taiwan, with data from INAVO120 under review with several other global health authorities.
About the INAVO120 studyThe INAVO120 study [NCT04191499] is a phase III, randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of Itovebi™ (inavolisib) in combination with palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer whose disease progressed during treatment or within 12 months of completing adjuvant endocrine therapy and who have not received prior systemic therapy for metastatic disease.12
The study included 325 patients, who were randomly assigned to either the investigational or control treatment arm.12 The primary endpoint is progression-free survival, as assessed by investigators, defined as the time from randomisation in the clinical trial to the time when the disease progresses, or a patient dies from any cause.12 Secondary endpoints include overall survival, objective response rate, and clinical benefit rate.12
Beyond INAVO120, Itovebi is currently being investigated in three company-sponsored phase III clinical studies in PIK3CA-mutated locally advanced or metastatic breast cancer in various combinations:
in combination with fulvestrant versus alpelisib plus fulvestrant in HR-positive/HER2-negative breast cancer post cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and endocrine combination therapy (INAVO121; NCT05646862).6
in combination with pertuzumab plus trastuzumab for subcutaneous injection (SC) versus pertuzumab plus trastuzumab for SC and optional physician's choice of endocrine therapy as a maintenance treatment in HER2-positive disease (INAVO122; NCT05894239).7
in combination with CDK4/6 inhibitor and letrozole versus placebo plus a CDK4/6 inhibitor and letrozole in the first-line setting in PIK3CA-mutated HR-positive/HER2-negative, endocrine-sensitive breast cancer (INAVO123; NCT06790693).8
About oestrogen receptor (ER)-positive breast cancerER-positive is a subtype of hormone receptor (HR)-positive breast cancer, the most prevalent type of all breast cancers, accounting for approximately 70% of cases.13,14 A defining feature of ER-positive breast cancer is that its tumour cells have receptors that attach to oestrogen, which can contribute to tumour growth.15
People diagnosed with ER-positive and HR-positive metastatic breast cancer often face the risk of disease progression and treatment side effects, creating a need for additional treatment options.14,16,17 The PI3K signalling pathway is commonly dysregulated in HR-positive breast cancer, often due to activating PIK3CA mutations, which have been identified as a potential mechanism of intrinsic resistance to standard of care endocrine therapy in combination with cyclin-dependent kinase 4/6 inhibitors.9
About Roche in breast cancerRoche has been advancing breast cancer research for more than 30 years with the goal ofhelping as many people with the disease as possible. Our medicines, along with companiondiagnostic tests, have contributed to bringing breakthrough outcomes in human epidermal growth factor 2-positive and triple-negative breast cancers. As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for other subtypes of the disease, including oestrogen receptor-positive breast cancer, which is a form of hormone receptor-positive breast cancer, the most prevalent type of all breast cancers.13,14
About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.References[1] Turner NC, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. NEJM. 2024;391(17):1584-96.[2] Cizkova M, et al. Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway. PLoS One. 2010;30;5(12):e15647.[3] Schagerholm C, et al. PIK3CA mutations in endocrine-resistant breast cancer. Scientific Reports. 2024;14:12542.[4] Fillbrunn M, et al. PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: a meta-analysis of published clinical trials. BMC Cancer. 2022;22(1):1002.[5] Jhaveri KL, et al. Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer. 2025;40454641.[6] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121) [Internet; cited 2025 June]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05646862. [7] ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (INAVO122) [Internet; cited 2025 June]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05894239. [8] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (INAVO123) [Internet; cited 2025 June]. Available from: https://clinicaltrials.gov/study/NCT06790693.[9] Anderson E, et al. A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer. Int J Breast Cancer. 2020;2020:3759179.[10] Juric D, et al. A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA-mutated hormone receptor-positive/HER2-negative (HR+/HER2–) metastatic breast cancer. Presented at San Antonio Breast Cancer Symposium, 2020 December 7-10; San Antonio, USA. Abstract #P5-17-05.[11] Hong R, et al. GDC-0077 is a selective PI3K alpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies. Cancer Res. 2018;78(4):4-14.[12] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120) [Internet; cited 2025 June]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04191499.[13] National Cancer Institute: Surveillance, Epidemiology and Ends Result Program. Cancer Stat Facts: Female Breast Cancer Subtypes [Internet; cited 2025 June]. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html.[14] Lim E, et al. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park). 2012;26(8):688-94,696.[15] Wu VS, et al. From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer? J Steroid Biochem Mol Biol. 2015 Sep;153:45-53.[16] Tomas R and Barrios CH. Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol. 2015;7(6):304-20.[17] Galipeau N, et al. Understanding key symptoms, side effects, and impacts of HR+/HER- advanced breast cancer: qualitative study findings. J Patient-Rep Outcomes. 2019;3(1):10.Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhDPhone: +41 79 407 72 58
Sileia UrechPhone: +41 79 935 81 48
Nathalie AltermattPhone: +41 79 771 05 25
Lorena CorfasPhone: +41 79 568 24 95
Simon GoldsboroughPhone: +44 797 32 72 915
Karsten KleinePhone: +41 79 461 86 83
Kirti PandeyPhone: +49 172 6367262
Yvette PetillonPhone: +41 79 961 92 50
Dr Rebekka SchnellPhone: +41 79 205 27 03
Roche Investor Relations
Dr Bruno EschliPhone: +41 61 68-75284e-mail: bruno.eschli@roche.com
Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: sabine.borngraeber@roche.com
Dr Birgit MasjostPhone: +41 61 68-84814e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren KalmPhone: +1 650 225 3217e-mail: kalm.loren@gene.com
Attachment
Media Investor Release EC approves Itovebi English
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Neither Scales Nor Feathers: Bizarre Appendage Discovered on Reptile Fossil
A bizarre reptile once scurried through the Triassic treetops with an extravagant crest on its back, one made from neither scale, nor bone, nor feather. The extinct creature's 247-million-year-old fossils immediately stood out to paleontologists. The impressive appendage on its back looks like a frill of overlapping feathers at first glance, but it's much older than the earliest fossilized feather, and there's no branching to indicate a plume. The elaborate structure also lacks bony spines, such as those seen in later dinosaurs, like Spinosaurus. Related: "This had to be something new," Stuttgart State Museum of Natural History paleontologist Stephan Spiekman told ScienceAlert. "Prior to our discovery, complex outgrowths from the skin were restricted to mammals and birds and their closest relatives, predominantly in the form of feathers and hair. "We now have another, different type of complex appendage, in a very early reptile." Long before dinosaurs evolved plumage, it appears that some early reptiles were already putting together a genetic toolkit for complex appendages. The dorsal crests discovered by Spiekman and his colleagues are "basically novel to science", so they don't yet have a name. In their study, the researchers essentially refer to them as skin outgrowths, but they aren't actually similar to reptile skin. Spiekman thinks the outgrowths may be made of keratin, similar to nails, hairs, scales, or claws. Confirming that suspicion will require further analysis. Altogether, Spiekman and his colleagues studied more than 80 fossils of the outgrowths, recently donated to the State Museum of Natural History in Stuttgart, Germany. The vast majority had lost their corresponding skeletons; only one of the fossils featured the bird-like skull of a small, ancient reptile. The extinct animal has been named Mirasaura grauvogeli, the first part of which means 'wonderous reptile'. Technically, the species is a drepanosaur – a small, early reptile that lived in the trees, hunting insects with its velociraptor-like claws. But its crest is the real stand-out feature. "Mirasaura developed an alternative to feathers very early in Earth's history, long before the dinosaurs, which we did not expect and which will stimulate discussion and research," says reptile paleontologist Rainer Schoch, from the State Museum of Natural History in Stuttgart. The exact function of the Mirasaura's dorsal appendage is unknown, but based on the physics, it probably wasn't used for flight or insulation. A role in visual communication, such as predator deterrence or intraspecies signaling, is more likely. The best preserved Mirasaura fossils were found to contain traces of melanosomes, which are organelles within pigment cells. Interestingly, their geometry is consistent with the melanosomes that color feathers, but not those found in reptile skin or mammal hair. "Mirasaura really shows how surprising evolution can be, and how much we can still learn from palaeontology," Spiekman told ScienceAlert. "We already knew from genetics and developmental biology that much of the pathway to form feathers, hairs, and scales, is shared between mammals, reptiles, and birds. Now, with Mirasaura, we can say that such complex structures did indeed grow in other animals, too." Turns out, reptiles aren't the scaly, simple animals we often paint them out to be. They deserve more credit. The study was published in Nature. Related News America's Largest Crater Has Surprise Link to Grand Canyon, Study Finds 500-Million-Year-Old Fossil Suggests Ocean Origin For Spiders Secret Bone Armor Discovered Beneath Skins of Australian Lizards Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
FDA probes death of patient on Sarepta's Elevidys, partner Roche says death unrelated to therapy
(Reuters) -The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' muscular disorder gene therapy Elevidys. The death occurred on June 7, the agency said, sending shares of the company down more than 3% in extended trading. The patient with Duchenne muscular dystrophy, who died in Brazil, was treated with Elevidys but was not a participant in a clinical trial, Roche, which partners with Sarepta outside the U.S., told Reuters in an email. The reporting physician has assessed the death as unrelated to treatment with the gene therapy, Roche said, adding that the death was reported to the health authorities as required per local regulations, and that it was continuing to gather and analyze the information from this event. Sarepta has come under intense regulatory scrutiny after two non-ambulatory teenage boys died due to acute liver failure associated with Elevidys, and a 51-year-old man who had received its experimental gene therapy SRP-9004 died from the same condition. Late on Monday, the company said it would comply with a request from the FDA to pause all shipments of Elevidys in the United States. Its partner Roche also paused Elevidys shipments in some countries outside the U.S. later. The FDA's request had come after the company disclosed the death of the patient on SRP-9004.
Yahoo
an hour ago
- Yahoo
Visteon Q2 net income falls amid slowed EV production and decrease in China demand
Visteon Corp., a global supplier of electronics and vehicle connectivity parts, said second-quarter net income fell 8.45 percent to $65 million because of lower electric vehicle production and a decrease in demand from China customers. Revenue fell to $969 million, down $45 million from the second quarter of last year. 'Net sales of $969 million came in higher than we had anticipated at the beginning of the quarter, driven by strong demand for our digital content products, particularly in North America and Europe,' CEO Sachin Lawande said during the company's call with analysts July 24. 'Despite the robust sales performance, lower [battery management systems] sales in the U.S. and the ongoing market dynamics in China resulted in sales slightly underperforming customer vehicle production.' Sign up for Automotive News breaking news alerts and be the first to know when big news happens. Lawande said future sales will depend on how automakers react to the elimination of the U.S. EV tax credit, set to take effect Sept. 30. Visteon was able to emerge relatively unscathed by tariff costs that have affected other companies, as the vast majority of its products are compliant with the United States-Mexico-Canada Agreement currently not subject to tariffs. The company secured $2 billion in new business in the second quarter, bringing the year-to-date total to $3.9 billion. Visteon launched 21 products across eight automakers, with key products including a 25-inch display for the Audi Q3 platform in Europe and SmartCore domain controller programs for the Volvo EX30 electric crossover, Volvo construction vehicles and the Polestar 5. Visteon shares closed up 0.83 percent on July 24. Visteon, of Van Buren Township, Mich., ranks No. 59 on Automotive News' list of top 100 global suppliers, with $3.9 billion in parts sales to automakers in 2024. Send us a letter to the editor Have an opinion about this story? Tell us about it and we may publish it in print. Click here to submit a letter to the editor.
